Altered metabolite levels in cancer: Implications for tumour biology and cancer therapy

Nature Reviews Cancer

Volumn 16, Issue 11, 2016, Pages 680-693

  Sullivan, Lucas B ^a   Gui, Dan Y ^a   Van Der Heiden, Matthew G ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ASPARTIC ACID; DEXTRO 2 HYDROXYGLUTARATE; ELECTROPHILE; FUMARIC ACID; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR; METHYLGLYOXAL; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; SUCCINIC ACID; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ENZYME; PROTEIN; TUMOR MARKER;

CANCER CELL; CANCER THERAPY; CARBOXYLATION; CELL METABOLISM; ENZYME ACTIVITY; GLYCOLYSIS; HUMAN; LIPID PEROXIDATION; MALIGNANT NEOPLASTIC DISEASE; METABOLITE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; GENE EXPRESSION; GENETICS; METABOLISM; MUTATION; NEOPLASM; PROTEIN SYNTHESIS;

BIOMARKERS, TUMOR; ENZYMES; GENE EXPRESSION; HUMANS; MUTATION; NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEINS; SIGNAL TRANSDUCTION;

EID: 84988615398     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.85     Document Type: Review

References (189)

1. Hu, J., et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 31, 522-529 (2013
2. Liberti, M. V., & Locasale, J. W. The Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 41, 211-218 (2016
3. Pavlova, N. N., & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27-47 (2016
4. Ying, H., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670 (2012
5. Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C., & Martins, C. P. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature 531, 110-113 (2016
6. Davidson, S. M., et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 23, 517-528 (2016
7. Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. MYC, metabolism, and cancer. Cancer Discov. 5, 1024-1039 (2015
8. Li, T., et al. Tumor suppression in the absence of p53 mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269-1283 (2012
9. Tennant, D. A., Duran, R. V., & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277 (2010
10. Vander Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10, 671-684 (2011
11. Menendez, J. A., & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763-777 (2007
12. Gottlieb, E., & Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5, 857-866 (2005
13. Locasale, J. W., et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43, 869-874 (2011
14. Possemato, R., et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350 (2011
15. Dillon, B. J., et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100, 826-833 (2004
16. Grompe, M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin. Liver Dis. 21, 563-571 (2001
17. Dang, L., et al. Cancer-associated IDH1 mutations produce 2 hydroxyglutarate. Nature 462, 739-744 (2009
18. Ward, P. S., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2 hydroxyglutarate. Cancer Cell 17, 225-234 (2010
19. Tomlinson, I. P., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406-410 (2002
20. Adam, J., et al. A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia. Cell Rep. 3, 1440-1448 (2013
21. Wallace, D. C. Mitochondria and cancer. Nat. Rev. Cancer 12, 685-698 (2012
22. Astuti, D., et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 69, 49-54 (2001
23. Janeway, K. A., et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc. Natl Acad. Sci. USA 108, 314-318 (2011
24. Bardella, C., Pollard, P. J., & Tomlinson, I. SDH mutations in cancer. Biochim. Biophys. Acta 1807, 1432-1443 (2011
25. Selak, M. A., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7, 77-85 (2005
26. Delage, B., et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int. J. Cancer 126, 2762-2772 (2010
27. Rabinovich, S., et al. Diversion of aspartate in ASS1 deficient tumours fosters de novo pyrimidine synthesis. Nature 527, 379-383 (2015
28. Hamanaka, R. B., & Chandel, N. S. Targeting glucose metabolism for cancer therapy. J. Exp. Med. 209, 211-215 (2012
29. Gillies, R. J., Robey, I., & Gatenby, R. A. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49 (Suppl. 2), 24S-42S (2008
30. Clark, O., Yen, K., & Mellinghoff, I. K. Molecular pathways: isocitrate dehydrogenase mutations in cancer. Clin. Cancer Res. 22, 1837-1842 (2016
31. Choi, C., et al. 2 Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 18, 624-629 (2012
32. Sullivan, L. B., et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell 162, 552-563 (2015
33. Birsoy, K., et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162, 540-551 (2015
34. Zhang, J., et al. Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol. Cell 56, 205-218 (2014
35. Lin, C. C., et al. Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy. Sci. Rep. 2, 785 (2012
36. Schell, J. C., et al. A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol. Cell 56, 400-413 (2014
37. Hitosugi, T., et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol. Cell 44, 864-877 (2011
38. Dupuy, F., et al. PDK1 dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab. 22, 577-589 (2015
39. Zheng, L., et al. Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer Metab. 1, 12 (2013
40. Frezza, C., et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477, 225-228 (2011
41. Christofk, H. R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008
42. Keller, K. E., Tan, I. S., & Lee, Y. S. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 338, 1069-1072 (2012
43. Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M., & Cantley, L. C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181-186 (2008
44. Chaneton, B., et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491, 458-462 (2012
45. Mazurek, S., Boschek, C. B., Hugo, F., & Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 15, 300-308 (2005
46. Israelsen, W. J., et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155, 397-409 (2013
47. Anastasiou, D., et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334, 1278-1283 (2011
48. Kung, C., et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem. Biol. 19, 1187-1198 (2012
49. Anastasiou, D., et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8, 839-847 (2012
50. Lunt, S. Y., et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol. Cell 57, 95-107 (2015
51. Ye, J., et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl Acad. Sci. USA 109, 6904-6909 (2012
52. Metallo, C. M., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380-384 (2012
53. Mullen, A. R., et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385-388 (2012
54. Wise, D. R., et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl Acad. Sci. USA 108, 19611-19616 (2011
55. Scott, D. A., et al. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J. Biol. Chem. 286, 42626-42634 (2011
56. Fendt, S. M., et al. Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells. Nat. Commun. 4, 2236 (2013
57. Gameiro, P. A., et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 17, 372-385 (2013
58. Xu, W., et al. Oncometabolite 2 hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30 (2011
59. Chowdhury, R., et al. The oncometabolite 2 hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463-469 (2011
60. Sasaki, M., et al. d-2 Hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 26, 2038-2049 (2012
61. Kaelin, W. G. Jr. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2 oxoglutarate-dependent dioxygenases. Cold Spring Harb. Symp. Quant. Biol. 76, 335-345 (2011
62. Loenarz, C., & Schofield, C. J. Expanding chemical biology of 2 oxoglutarate oxygenases. Nat. Chem. Biol. 4, 152-156 (2008
63. Figueroa, M. E., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567 (2010
64. Lu, C., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474-478 (2012
65. Turcan, S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483 (2012
66. Lu, C., et al. Induction of sarcomas by mutant IDH2. Genes Dev. 27, 1986-1998 (2013
67. Chi, P., Allis, C. D., & Wang, G. G. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10, 457-469 (2010
68. Flavahan, W. A., et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529, 110-114 (2016
69. Rohle, D., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626-630 (2013
70. Wang, F., et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622-626 (2013
71. Losman, J. A., et al. (R)-2 hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621-1625 (2013
72. Saha, S. K., et al. Mutant IDH inhibits HNF 4α to block hepatocyte differentiation and promote biliary cancer. Nature 513, 110-114 (2014
73. Shih, A. H., Abdel-Wahab, O., Patel, J. P., & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12, 599-612 (2012
74. Aghili, M., Zahedi, F., & Rafiee, E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J. Neurooncol. 91, 233-236 (2009
75. Fan, J., et al. Human phosphoglycerate dehydrogenase produces the oncometabolite d-2 hydroxyglutarate. ACS Chem. Biol. 10, 510-516 (2015
76. Oldham, W. M., Clish, C. B., Yang, Y., & Loscalzo, J. Hypoxia-mediated increases in l-2 hydroxyglutarate coordinate the metabolic response to reductive stress. Cell Metab. 22, 291-303 (2015
77. Intlekofer, A. M., et al. Hypoxia induces production of l-2 hydroxyglutarate. Cell Metab. 22, 304-311 (2015
78. Shim, E. H., et al. l-2 Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 4, 1290-1298 (2014
79. Terunuma, A., et al. MYC-driven accumulation of 2 hydroxyglutarate is associated with breast cancer prognosis. J. Clin. Invest. 124, 398-412 (2014
80. Xiao, M., et al. Inhibition of α KG dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 26, 1326-1338 (2012
81. Letouze, E., et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 23, 739-752 (2013
82. Killian, J. K., et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 3, 648-657 (2013
83. Hoekstra, A. S., et al. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors. Oncotarget 6, 38777-38788 (2015
84. Isaacs, J. S., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153 (2005
85. Pollard, P. J., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231-2239 (2005
86. Gimenez-Roqueplo, A. P., et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 69, 1186-1197 (2001
87. Hewitson, K. S., et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J. Biol. Chem. 282, 3293-3301 (2007
88. Koivunen, P., et al. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J. Biol. Chem. 282, 4524-4532 (2007
89. O'Flaherty, L., et al. Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum. Mol. Genet. 19, 3844-3851 (2010
90. MacKenzie, E. D., et al. Cell-permeating α-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol. Cell. Biol. 27, 3282-3289 (2007
91. Adam, J., et al. Renal cyst formation in Fh1 deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20, 524-537 (2011
92. Szatrowski, T. P., & Nathan, C. F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51, 794-798 (1991
93. Irani, K., et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275, 1649-1652 (1997
94. Weinberg, F., et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA 107, 8788-8793 (2010
95. Karisch, R., et al. Global proteomic assessment of the classical protein-tyrosine phosphatome and Redoxome. Cell 146, 826-840 (2011
96. Arnold, R. S., et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc. Natl Acad. Sci. USA 98, 5550-5555 (2001
97. Suh, Y. A., et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature 401, 79-82 (1999
98. Sullivan, L. B., & Chandel, N. S. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2, 17 (2014
99. Bell, E. L., Emerling, B. M., Ricoult, S. J., & Guarente, L. SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene 30, 2986-2996 (2011
100. Finley, L. W., et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell 19, 416-428 (2011
101. Park, J. S., et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum. Mol. Genet. 18, 1578-1589 (2009
102. Sharma, L. K., et al. Mitochondrial respiratory complex I dysfunction promotes tumorigenesis through ROS alteration and AKT activation. Hum. Mol. Genet. 20, 4605-4616 (2011
103. Ishikawa, K., et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320, 661-664 (2008
104. Baty, J. W., Hampton, M. B., & Winterbourn, C. C. Proteomic detection of hydrogen peroxide-sensitive thiol proteins in Jurkat cells. Biochem. J. 389, 785-795 (2005
105. Peralta, D., et al. A proton relay enhances H2O2 sensitivity of GAPDH to facilitate metabolic adaptation. Nat. Chem. Biol. 11, 156-163 (2015
106. Cox, A. G., Winterbourn, C. C., & Hampton, M. B. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem. J. 425, 313-325 (2010
107. Sobotta, M. C., et al. Peroxiredoxin 2 and STAT3 form a redox relay for H2O2 signaling. Nat. Chem. Biol. 11, 64-70 (2015
108. Woo, H. A., et al. Inactivation of peroxiredoxin I by phosphorylation allows localized H2O2 accumulation for cell signaling. Cell 140, 517-528 (2010
109. Lee, S. R., et al. Reversible inactivation of the tumor suppressor PTEN by H2O2. J. Biol. Chem. 277, 20336-20342 (2002
110. Denu, J. M., & Tanner, K. G. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 37, 5633-5642 (1998
111. Lee, G., et al. Oxidative dimerization of PHD2 is responsible for its inactivation and contributes to metabolic reprogramming via HIF 1α activation. Sci. Rep. 6, 18928 (2016
112. Gerald, D., et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118, 781-794 (2004
113. Hakimi, A. A., et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104-116 (2016
114. Kim, D., et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature 520, 363-367 (2015
115. Lo, T. W., Westwood, M. E., McLellan, A. C., Selwood, T., & Thornalley, P. J. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with Nα-acetylarginine, Nα-acetylcysteine, and Nα-acetyllysine, and bovine serum albumin. J. Biol. Chem. 269, 32299-32305 (1994
116. Rabbani, N., & Thornalley, P. J. Dicarbonyl proteome and genome damage in metabolic and vascular disease. Biochem. Soc. Trans. 42, 425-432 (2014
117. Sousa Silva, M., Gomes, R. A., Ferreira, A. E., Ponces Freire, A., & Cordeiro, C. The glyoxalase pathway: the first hundred years and beyond. Biochem. J. 453, 1-15 (2013
118. Van Heijst, J. W., Niessen, H. W., Hoekman, K., & Schalkwijk, C. G. Advanced glycation end products in human cancer tissues: detection of Nϵ-(carboxymethyl) lysine and argpyrimidine. Ann. NY Acad. Sci. 1043, 725-733 (2005
119. Chiavarina, B., et al. Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes. Oncotarget 5, 5472-5482 (2014
120. Santarius, T., et al. GLO1 - a novel amplified gene in human cancer. Genes Chromosomes Cancer 49, 711-725 (2010
121. Hosoda, F., et al. Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer. Oncogene 34, 1196-1206 (2015
122. Zhang, S., et al. Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 7, 2079-2090 (2014
123. Guo, Y., et al. Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl 2. Cancer Biol. Ther. 17, 169-180 (2016
124. Zender, L., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135, 852-864 (2008
125. Vistoli, G., et al. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic. Res. 47 (Suppl. 1), 3-27 (2013
126. Moellering, R. E., & Cravatt, B. F. Functional lysine modification by an intrinsically reactive primary glycolytic metabolite. Science 341, 549-553 (2013
127. Sullivan, L. B., et al. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol. Cell 51, 236-248 (2013
128. Zheng, L., et al. Fumarate induces redox-dependent senescence by modifying glutathione metabolism. Nat. Commun. 6, 6001 (2015
129. Sudarshan, S., et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1α stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell. Biol. 29, 4080-4090 (2009
130. Bardella, C., et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J. Pathol. 225, 4-11 (2011
131. Joseph, N. M., et al. Morphology and immunohistochemistry for 2SC and FH aid in detection of fumarate hydratase gene aberrations in uterine leiomyomas from young patients. Am. J. Surg. Pathol. 39, 1529-1539 (2015
132. Ternette, N., et al. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep. 3, 689-700 (2013
133. Tong, W. H., et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 20, 315-327 (2011
134. Jorquera, R., & Tanguay, R. M. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem. Biophys. Res. Commun. 232, 42-48 (1997
135. Lantum, H. B., Liebler, D. C., Board, P. G., & Anders, M. W. Alkylation and inactivation of human glutathione transferase zeta (hGSTZ1 1) by maleylacetone and fumarylacetone. Chem. Res. Toxicol. 15, 707-716 (2002
136. Lindblad, B., Lindstedt, S., & Steen, G. On the enzymic defects in hereditary tyrosinemia. Proc. Natl Acad. Sci. USA 74, 4641-4645 (1977
137. Jorquera, R., & Tanguay, R. M. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum. Mol. Genet. 10, 1741-1752 (2001
138. Grompe, M., et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat. Genet. 10, 453-460 (1995
139. Angileri, F., et al. Molecular changes associated with chronic liver damage and neoplastic lesions in a murine model of hereditary tyrosinemia type 1. Biochim. Biophys. Acta 1852, 2603-2617 (2015
140. Marhenke, S., et al. Activation of nuclear factor E2 related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. Hepatology 48, 487-496 (2008
141. Willenbring, H., et al. Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell 14, 59-67 (2008
142. Al Dhalimy, M., Overturf, K., Finegold, M., & Grompe, M. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol. Genet. Metab. 75, 38-45 (2002
143. Weinberg, A. G., Mize, C. E., & Worthen, H. G. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J. Pediatr. 88, 434-438 (1976
144. Spitz, D. R., Sullivan, S. J., Malcolm, R. R., & Roberts, R. J. Glutathione dependent metabolism and detoxification of 4 hydroxy 2 nonenal. Free Radic. Biol. Med. 11, 415-423 (1991
145. Levonen, A. L., et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem. J. 378, 373-382 (2004
146. Karihtala, P., Kauppila, S., Puistola, U., & Jukkola-Vuorinen, A. Divergent behaviour of oxidative stress markers 8 hydroxydeoxyguanosine (8 OHdG) and 4 hydroxy 2 nonenal (HNE) in breast carcinogenesis. Histopathology 58, 854-862 (2011
147. Hamanaka, R. B., & Chandel, N. S. Mitochondrial reactive oxygen species regulate hypoxic signaling. Curr. Opin. Cell Biol. 21, 894-899 (2009
148. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. HIF 1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3, 187-197 (2006
149. Kim, J. W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. HIF 1 mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177-185 (2006
150. Tello, D., et al. Induction of the mitochondrial NDUFA4L2 protein by HIF 1α decreases oxygen consumption by inhibiting complex I activity. Cell Metab. 14, 768-779 (2011
151. Dinkova-Kostova, A. T., et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl Acad. Sci. USA 99, 11908-11913 (2002
152. Fourquet, S., Guerois, R., Biard, D., & Toledano, M. B. Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. J. Biol. Chem. 285, 8463-8471 (2010
153. Ooi, A., et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20, 5 11-523 (2011
154. Dieter, M. Z., et al. Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress. Free Radic. Biol. Med. 35, 351-367 (2003
155. Sporn, M. B., & Liby, K. T. NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12, 564-571 (2012
156. Jaramillo, M. C., & Zhang, D. D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27, 2179-2191 (2013
157. DeNicola, G. M., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109 (2011
158. Satoh, H., Moriguchi, T., Takai, J., Ebina, M., & Yamamoto, M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res. 73, 4158-4168 (2013
159. Sayin, V. I., et al. Antioxidants accelerate lung cancer progression in mice. Sci. Transl Med. 6, 221ra215 (2014
160. Omenn, G. S., et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334, 1150-1155 (1996
161. Klein, E. A., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306, 1549-1556 (2011
162. Xue, M., et al. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem. J. 443, 213-222 (2012
163. Langlois, C., et al. Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment. Mol. Genet. Metab. 93, 306-313 (2008
164. Jorquera, R., & Tanguay, R. M. Cyclin B dependent kinase and caspase 1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis. FASEB J. 13, 2284-2298 (1999
165. Deng, G., et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J. Biol. Chem. 290, 762-774 (2015
166. Davis, M. I., et al. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J. Biol. Chem. 289, 13717-13725 (2014
167. Popovici-Muller, J., et al. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2 HG in vivo. ACS Med. Chem. Lett. 3, 850-855 (2012
168. Andronesi, O. C., et al. Detection of 2 hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci. Transl Med. 4, 116ra114 (2012
169. De la Fuente, M. I., et al. Integration of 2 hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro Oncol. 18, 283-290 (2016
170. Andronesi, O. C., et al. Treatment response assessment in IDH-mutant glioma patients by noninvasive 3D functional spectroscopic mapping of 2 hydroxyglutarate. Clin. Cancer Res. 22, 1632-1641 (2016
171. Tateishi, K., et al. Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell 28, 773-784 (2015
172. Mullen, A. R., et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep. 7, 1679-1690 (2014
173. Cardaci, S., et al. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat. Cell Biol. 17, 1317-1326 (2015
174. Lussey-Lepoutre, C., et al. Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat. Commun. 6, 8784 (2015
175. Long, Y., et al. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol. Cancer Ther. 12, 2581-2590 (2013
176. Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. Pegylated arginine deiminase (ADI SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 62, 5443-5450 (2002
177. Miraki-Moud, F., et al. Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Blood 125, 4060-4068 (2015
178. Tomlinson, B. K., et al. Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors. Clin. Cancer Res. 21, 2480-2486 (2015
179. Zou, X. Y., et al. Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma. J. Invest. Dermatol. 135, 589-598 (2015
180. Sakamoto, H., et al. Selective activation of apoptosis program by S p bromobenzylglutathione cyclopentyl diester in glyoxalase I overexpressing human lung cancer cells. Clin. Cancer Res. 7, 2513-2518 (2001
181. Thornalley, P. J., et al. Antitumour activity of S p bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochem. Pharmacol. 51, 1365-1372 (1996
182. Kuhla, B., et al. Pathological effects of glyoxalase I inhibition in SH SY5Y neuroblastoma cells. J. Neurosci. Res. 83, 1591-1600 (2006
183. Raj, L., et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475, 231-234 (2011
184. Trachootham, D., et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241-252 (2006
185. Yang, W. S., et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317-331 (2014
186. Harris, I. S., et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27, 211-222 (2015
187. Piskounova, E., et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186-191 (2015
188. Le Gal, K., et al. Antioxidants can increase melanoma metastasis in mice. Sci. Transl Med. 7, 308re308 (2015
189. Hanahan, D., & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011